Esperion CFO Benjamin Halladay Sells Shares

On June 17, 2026, Benjamin Halladay, the Chief Financial Officer of Esperion Therapeutics, Inc. (NasdaqGM: ESPR), sold 10,773 shares of the company. The shares were sold at an average price of $3.16, totaling approximately $34,042.68. This transaction was not made under a pre-planned trading program.

Insider Buying and Selling at Esperion Therapeutics, Inc.

In addition to Halladay's sale, other insiders at Esperion also made transactions on the same day. Sheldon Koenig, the President and CEO, sold 53,588 shares, and Benjamin Looker, the Chief Legal Officer, sold 11,824 shares, both at the same price of $3.16 per share. These sales were also not part of any pre-arranged plans. Earlier, on May 28, 2026, Seth Fischer and John Craig Thompson each acquired 79,873 shares, although these were done at a price of $0.

Other Institutional Activity in Esperion Therapeutics

Several institutional investors have recently adjusted their positions in Esperion Therapeutics. Wasatch Advisors LP significantly increased its holdings by adding 6,323,138 shares, bringing its total to 15,768,897 shares valued at about $43.2 million, marking a 66.9% increase. OrbiMed Advisors LLC also expanded its stake by 4,604,802 shares, now holding 10,570,300 shares worth approximately $28.96 million, reflecting a 77.2% rise. Meanwhile, Two Seas Capital LP reduced its position by 507,688 shares, now holding 11,394,833 shares valued at $31.22 million, a decrease of 4.3%.

Esperion Therapeutics Stock Snapshot

Shares of Esperion Therapeutics traded near $3.15 on Friday. The company, which operates in the healthcare sector as a drug manufacturer, has a market capitalization of about $811.7 million. It currently has a forward P/E ratio of 10.79 and a beta of 1.067, indicating moderate volatility compared to the market. The stock's 52-week range has been between $0.95 and $4.18, with a 50-day moving average of $2.78 and a 200-day moving average of $3.02.

Recent Earnings

Esperion Therapeutics reported revenue of $418.2 million, with a growth rate of 23.2%. However, the company posted a negative net margin of 1.78%. The next earnings report is expected on August 4, 2026.

Analysts Set New Price Targets

On May 1, 2026, HC Wainwright & Co. downgraded Esperion Therapeutics to a 'hold' rating with a price target of $3.16. The consensus among analysts is a 'buy' rating, with a mean target price of $3.19, based on four analyst opinions.

About Esperion Therapeutics

Esperion Therapeutics, Inc., based in Ann Arbor, Michigan, is a biopharmaceutical company focused on developing and marketing treatments for elevated LDL cholesterol. Its main products include NEXLETOL and NEXLIZET, which are non-statin oral medications targeting cholesterol issues. The company collaborates with various international pharmaceutical firms and is led by CEO Sheldon L. Koenig.

Bottom Line

Insider transactions at Esperion Therapeutics, like those by CFO Benjamin Halladay, draw attention as they can suggest how company executives view stock value. Investors closely watch such moves along with institutional activity to gauge confidence levels. It's important to remember that 13F filings and insider transactions reflect past positions and actions, not necessarily the current outlook.